Since 28-8 and 22C3, that were often used in clinical studies, showed high concordance with SP263 in terms of PD-L1 expression on tumour cells,24 SP142 was reported to be an outlier that detected significantly less PD-L1 expression compared with the other clones.25–27 In KEYNOTE062, a Phase 3 trial comparing the efficacy of cytotoxic chemotherapy combined with pembrolizumab vs. only cytotoxic chemotherapy vs. only pembrolizumab as first-line therapy for GC, pembrolizumab demonstrated a meaningful improvement in OS in PD-L1 CPS ≥ 10 subgroups,28 which supports our results. The gene discussed is CD274; the disease is gastric cancer.